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Abstract 
Aim. This article describes the rationale, design and methodology of the Building research initiative group: chronic 
illness management and adherence in transplantation (BRIGHT) study. This study of heart transplant patients will: 
(1) describe practice patterns relating to chronic illness management; (2) assess prevalence and variability of non‐
adherence to the treatment regimen; (3) determine the multi‐level factors related to immunosuppressive medication 
non‐adherence.  
Background. The unaltered long‐term prognosis after heart transplantation underscores an urgent need to identify and 
improve factors related to survival outcomes. The healthcare system (e.g. level of chronic illness management 
implemented) and patient self‐management are major drivers of outcome improvement. 
Design. The study uses a survey design in 40 heart transplant centres covering 11 countries in four continents. 
Methods. Theoretical frameworks informed variable selection, which are measured by established and investigator‐
developed instruments. Heart transplant recipients, outpatient clinicians and programme's directors complete a 
survey. A staged convenience sampling strategy is implemented in heart transplant centres, countries and continents. 
Depending on the centre's size, a random sample of 25–60 patients is selected (N estimated 1680 heart transplant 
recipients). Five randomly selected clinicians and the medical director from each centre will be invited to participate. 
Conclusion. This is the first multi‐centre, multi‐continental study examining healthcare system and heart transplant 
centres chronic illness management practice patterns and potential correlates of immunosuppressive medication non‐
adherence. The knowledge gained will inform clinicians, researchers and healthcare policy makers at which level(s) 
interventions need to be implemented to improve long‐term outcomes for transplant recipients. 
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Over the past decades, survival rates in heart transplant (HTx) recipients have improved largely due to 
advances in immunosuppressive medication regimens and better surgical techniques but are limited to the 
first 12 months post transplantation. Long‐term survival remains largely unchanged (Lodhi et al. 2011, 
Stehlik et al. 2012), indicating the urgent need to identify and improve factors related to long‐term 
survival outcomes. Evidence in other chronically ill patient populations shows that the healthcare system 
(e.g. level of chronic illness management (CIM)) and patient self‐management (e.g. adherence) drive 
improvements in outcomes (Nuno et al. 2012).  
Background 
The level of CIM refers to the extent to which the principles of CIM are implemented in the care of 
chronically ill patients e.g. HTx recipients who require lifelong medical follow‐up and active patient 
engagement in a variety of health behaviours. These include medication taking, regular physical activity, 
reducing/stopping alcohol intake, sun protection, non‐smoking and keeping medical appointments. 
Despite their chronic condition, healthcare for this population is commonly organized around an acute, 
episodic model, typically focuses on detection and treatment of acute illnesses rather than preventive 
measures and promoting effective self‐management. In contrast CIM principles focus on continuity of 
care; partnerships with patients, families and communities; patient self‐management support; attention to 
preventive measures; decision making support; and use of clinical information systems (Bodenheimer 
et al. 2002, Yach 2002, Pruitt & Epping‐Jordan 2005, Nolte & McKee 2008). The Chronic Care Model 
(CCM), developed by Wagner and colleagues, provides a structure to create or redesign healthcare 
organizations and systems enhancing their capacity to manage long‐term health problems (Bodenheimer 
et al. 2002). The World Health Organization (WHO) adapted the CCM, adding community and policy 
aspects to give a global perspective (Epping‐Jordan et al. 2004). The Innovative Care for Chronic 
Conditions (ICCC) framework (Figure 1) proposes that the basis for better outcomes in chronically ill 
patients lies in forming partnerships between informed, motivated and prepared patients and families; a 
motivated healthcare team and informed community partners (Yach 2002, Epping‐Jordan et al. 2004). 
This triad is influenced by the healthcare organization, broader community and policy environment. In the 
ICCC framework healthcare organization building blocks are: promoting continuity and coordination; 
encouraging quality through leadership and incentives; organizing and equipping healthcare teams; using 
information systems and supporting self‐management and prevention (Yach 2002). Evidence shows that 
specifically trained nurses (e.g. nurse practitioners, clinical nurse specialists) are key players in the 
management and coordination of care for chronically ill patients and in improving health outcomes and 





Figure 1 The Innovative Care for Chronic Conditions (ICCC) framework (Yach 2002). 
Little information is available on practice patterns relating to CIM in transplant programmes 
worldwide. Bissonnette et al. (2013) utilized a quasi‐experimental design to test a CIM programme based 
on the CCM (shared decision making, self‐management strategies, adherence enhancing interventions and 
instruction on accessing community resources) in kidney transplantation in Canada. Patients in the 
intervention group were significantly more likely to reach targeted clinical outcomes, had fewer 
emergency room visits and hospital admissions and had more discussions about end‐stage treatment 
options relative to the control group, suggesting the value of this model for transplantation (Bissonnette 
et al. 2013). Evidence from other chronically ill populations shows that care based on the CCM/ICCC 
framework is more appropriate than the acute care model in preventing or minimizing the frequency and 
extent of exacerbations and complications (Kane et al. 2005) leading to fewer hospital admissions 
(Drewes et al. 2012); reduced risk of mortality (Drewes et al. 2012); improved quality‐of‐life (Coleman 
et al. 2009, Drewes et al. 2012); health behaviours improvements (e.g. physical activity, dietary habits, 
medication adherence) (de Bruin et al. 2012, Moullec et al. 2012); reductions in HbA1c, LDL cholesterol 
and arterial blood pressure (Coleman et al. 2009); and increased patient and caregiver satisfaction (de 
Bruin et al. 2012). In a systematic review examining the financial impact of the CCM components, more 
than half of the studies reported healthcare savings (de Bruin et al. 2011). In studies of other chronic 
illnesses, delivery system redesign and self‐management support were found to be the most influential 
factors (Nuno et al. 2012).  
 
The evidence that self‐management support improves outcomes in the chronically ill emphasizes the 
relevance of patient health behaviours. Non‐adherence is defined as the extent to which a person's 
behaviour in medication taking, following a diet and/or executing lifestyle changes diverges from the 
agreed on healthcare provider recommendations (Sabaté 2003). Non‐adherence to various health 
behaviours ranges widely between 3·2–47%, depending on the measurement methods, operational 
definitions and sampling methodology. Eleven to 40% of the HTx patients (about 14·5 cases per 100 
patients annually) are non‐adherent to their immunosuppressive regimen (De Geest et al. 2005, Dew et al. 
2007, 2008, De Bleser et al. 2011) with, consequentially, higher rates of late acute rejections, chronic 
graft dysfunction, graft loss and mortality risk (Dew et al. 1999, Dobbels et al. 2004, De Geest et al. 
2011). Limited evidence shows rates of non‐adherence to co‐medications are higher. De Bleser and 
colleagues found a self‐reported co‐medication non‐adherence rate of 39·2% in HTx patients (De Bleser 
et al. 2011), higher than immunosuppressive non‐adherence. Between 3·2% and 47·2% of HTx patients 
smoke (Nagele et al. 1997, De Geest et al. 2005, Botha et al. 2008, Evangelista et al. 2009), which is 
associated with higher rates of malignancies, cardio allograft vasculopathy and mortality (Goldstein et al. 
1996, Curtil et al. 1997, Nagele et al. 1997, Botha et al. 2008). Almost five HTx recipients per 100 
annually are non‐adherent to recommendations to limit/quit alcohol use (Dew et al. 2007). Although the 
differences were not statistically significant, Owen et al. found that current or recent alcohol dependence 
increased the risk of post‐HTx hospitalization, infections and death (Owen et al. 2006). Non‐adherence to 
physical activity is prevalent with an estimated rate of 33·7 cases per 100 HTx annually (Dew et al. 
2007). Interventions encouraging higher levels of physical activity have been associated with improved 
outcomes including reductions in blood pressure, decreased hyperlipidaemia, increases in peak VO2 and 
better quality‐of‐life (Schmidt et al. 2002, Braith et al. 2008, Hermann et al. 2011). Dietary non‐
adherence ranges between 16–41·5% (De Geest et al. 2005), or 28·1 cases per 100 recipients annually 
(Dew et al. 2007). In the general population, non‐adherence to a prescribed diet (e.g. low sugar/salt/fat) is 
associated with an increased risk for development and progression of hypertension, diabetes and obesity 
(Lopez et al. 2008, Zhao et al. 2011). Non‐adherence to appointment keeping in HTx recipients ranges 
between 3–26·4% (Dew et al. 1996, De Geest et al. 2000, 2005) or 8·5 cases per 100 HTx patients 
annually (Dew et al. 2007), and has been associated with an increased risk in late acute rejections (De 
Geest et al. 2000). No information on the prevalence of non‐adherence to sun protection measures is 
available in HTx. Organ transplant recipients, however, are at higher risks of developing skin cancer due 
to the effects of long‐term drug‐induced immunosuppression (Feuerstein & Geller 2008, Zwald et al. 
2010).  
 
To improve patient's adherence to the treatment regimen, it is crucial to target interventions for 
modifiable factors influencing behaviour (Berben et al. 2012). The WHO identified five dimensions that 
determine medication adherence: (1) patient‐related factors (e.g. self‐efficacy and beliefs about the 
efficacy of treatment); (2) social and economic factors (e.g. literacy, level of education and social 
support); (3) therapy‐related factors (e.g. duration of treatment and dose complexity); (4) condition‐
related factors (e.g. comorbidities and depression); and (5) healthcare system and team‐related factors 
(e.g. trust in the healthcare team, level of CIM implemented). To‐date, most research on adherence has 
focused on medication non‐adherence. In these studies patient, socio‐economic, therapy and condition‐
related risk factors were examined in an attempt to explain the high rates of non‐adherence (Kidd & 
Altman 2000, Sabaté 2003). However, as a meta‐analysis in transplantation demonstrated, this group of 
risk factors accounts for a small portion of the observed variability (Dew et al. 2007) suggesting the need 
for more emphasis on healthcare system and healthcare team related risk factors.  
 
An expert panel on adherence of the American Heart Association recommended integrating strategies 
at the patient, provider and an organization level to optimize adherence management (Miller et al. 1997). 
The US Agency for Healthcare Research and Quality (Viswanathan et al. 2012a) concluded that 
adherence is a complex behaviour with multiple determinants. Clinical practice guidelines from the 
National Institute for Health and Clinical Excellence (NICE) (Nunes et al. 2009) strongly emphasize use 
of a systems approach in managing medication adherence. In 2010 the American Society of Hypertension 
recommended an ecological approach to increase patient adherence to anti‐hypertensive medications (Hill 
et al. 2010). It is not clear from previous studies which factors at which level(s) contribute to non‐
adherence. In their review, Viswanathan and colleagues concluded that additional research is needed to 
identify the specific multi‐level factors that most influence adherence (Viswanathan et al. 2012b).  
 
The BRIGHT study addresses these gaps in the literature by examining the extent to which HTx 
centres’ practice patterns reflect the ICCC model and the relationship between the level of CIM 
implemented and adherence to immunosuppressive medications. By collecting data on patient, healthcare 
provider, healthcare organization and healthcare system and policy‐level factors, a multi‐level approach 
will be used to examine the interrelating impact of individual factors and whether the combined effects of 
risk factors associated with immunosuppressive medication non‐adherence are additive or synergistic. 
The participation of centres in multiple countries and continents will give us the unique opportunity to 
benchmark CIM practice patterns, and patient non‐adherence relating to various aspects of the treatment 
regimen within and between countries and continents. 
The study 
Aims 
The primary aims of this study are: 
 
1. To describe CIM practice patterns among centres, countries/continents in HTx. 
2. To assess the prevalence and variability of non‐adherence to treatment regimen, i.e. medication 
taking, smoking cessation, diet keeping, alcohol consumption, physical activity, sun protection and 
appointment keeping in HTx recipients among centres, countries/continents. 
3. To determine which multi‐level factors are related to immunosuppressive medication adherence at 
the:  
 Patient level: i.e. patient beliefs, intentions, self‐efficacy and barriers, confidence in 
immunosuppressive medication taking, depression, health literacy 
 Healthcare provider level: i.e. patient satisfaction with the interpersonal dimension of care, 
trust in the transplant team, received social support 
 Healthcare organization level: i.e. CIM transplant programme practice patterns 
 Healthcare system and policy level: i.e. perceived financial burden of the treatment regimen, 
insurance status, system of healthcare coverage, country. 
4. To benchmark participating centres, countries and continents in relation to CIM practice patterns 
and non‐adherence to health behaviours. 
Conceptual framework 
The ecological model integrates healthcare system factors in explaining patient behaviour. It identifies 
factors at the patient, healthcare provider, healthcare organization and healthcare system and policy levels 
as important correlates of patient behaviours and provides a framework for assessing the extent to which 
components of the chronic illness model are incorporated in clinical settings. 
Design/methodology 
The BRIGHT study is an international multi‐centre, cross‐sectional study using a survey design. This 
study is managed by a project team consisting of the principle investigator, co‐investigators and project 
manager. The BRIGHT consortium, consisting of experts in organ transplantation from different 
disciplines and countries, serve as an advisory body for the project team which participate in bi‐weekly 
telephone conferences to discuss study progress. In addition, bi‐monthly telephone conferences are 
scheduled with all members of the BRIGHT consortium. This study is endorsed by several professional 
transplant and patient organizations. 
Sample/participants 
The BRIGHT study uses a multi‐staged sampling approach. A convenience sample of countries and 
HTx centres is recruited followed by a randomized sampling procedure for patients and clinicians. 
Countries included are: Australia; Belgium; Brazil; Canada; France; Germany; Italy; Spain; Switzerland; 
the UK; and the US. To be eligible, a country had to have at least two eligible HTx centres. 
  
HTx centres are invited to participate using the network of the International Transplant Nurses Society 
(ITNS), the International Society of Heart and Lung Transplantation (ISHLT) and contacts of the 
BRIGHT team members. HTx centres are eligible to participate in the study if: (1) ≥50 HTx have been 
performed during the 12–60 months prior to inclusion (i.e. about 10 transplant procedures annually); (2) 
the centre is located in Europe (Belgium, France, Germany, Italy, Spain, Switzerland or the UK); North 
America (Canada or the US); South America (Brazil) or Australia; and (3) the study is formally supported 
by the centre's transplant director and responsible administrator. 
 
In each centre, HTx clinicians are recruited using the following inclusion criteria: (1) worked in the 
centre >6 months; (2) employed ≥50% in direct clinical practice; and (3) familiar with the posttransplant 
outpatient care at the centre. Based on the number of eligible clinicians, we use a convenience (if ≤5 
clinicians are eligible, all are included) or a random (if >5 clinicians are eligible a random sample of 5 are 
selected) sample. 
 
HTx recipients are selected using a proportionate cluster randomized sampling strategy. Inclusion 
criteria for the patient are: (1) HTx recipient; (2) ≥18 years of age at time of inclusion; (3) transplanted 
and followed up for routine care in a participating transplant centre; (4) first transplant; (5) single‐organ 
transplant; (6) between 1–5 years posttransplant; (7) ability to read, understand and give a signature on an 
informed consent (in Dutch, English, French, German, Spanish, Italian, or Brazilian Portuguese, 
depending on the languages spoken in the country of the participating transplant centre); and (8) give 
written informed consent. Patients are excluded if they: (1) participated in adherence‐intervention 
research or drug trials during the past 6 months (participation in previous descriptive research is allowed); 
or (2) currently receive professional support in taking their medications. 
 
The sampling strategy is guided by known variability in the size of the centres relative to the number 
of transplant recipients in follow‐up and the number of yearly transplantations performed. Centres are 
therefore categorized into three groups based on the ISHLT criteria (International Society of Heart & 
Lung Transplantation 2011). Based on the 5‐year data, centres performing 50–74 HTx are classified as 
small, those performing 75–100 HTx as medium and those performing >100 HTx as large. A power 
analysis showed that a modest association (i.e. an odds ratio of 1·25) between adherence and the level of 
CIM implemented should be detectable with at least 28 patients per centre, assuming at least 40 centres 
and a power of 90%. With an estimated participation rate of 70%, on average, 40 patients per centre need 
to be invited to participate. This sample size will be obtained by including 40 centres and 25/40/60 
patients per centre respectively for small/medium/large size centres, reaching a total predicted sample size 
of 1680 HTx patients.  
Theoretical framework used to select variables 
Two theoretical frameworks combined with evidence from the literature were used to select the 
potential correlates of immunosuppressive medication non‐adherence: the Integrative Model of 
Behavioral Prediction (IMBP) (Figure 2) (Fishbein et al. 2003) for variables at the patient level and the 
ecological model (Figure 3) (Bronfenbrenner 1980, Berben et al. 2012) for healthcare system‐related 
variables. The IMBP describes behaviour as dependent on intentions and determinants of intentions are 
attitudes, norms and self‐efficacy. Although intention is the primary determinant of behaviour, lack of 
skills and abilities and environmental constraints or barriers may prevent a person from acting on his/her 
intentions (Fishbein et al. 2003). The ecological model takes the influence of multiple levels of the 
healthcare system into account in explaining behaviour. These are: the patient, healthcare provider level 
(i.e. factors related to social support and interpersonal or face‐to‐face relationships with healthcare 
professionals (Yach 2002)), the healthcare organization level (i.e. characteristics of the healthcare 
organization where the patient is treated (Yach 2002)) and the healthcare system and policy level (i.e. the 









Figure 3 Patient level: Modified Integrative Model of Behavioral Prediction (Fishbein et al. 2003, Schmid‐Mohler et al. 2010). 
Variables are measured using established instruments or investigator‐developed measures. The 
instruments are described in detail in (Tables S1–S6). CIM practice patterns are collected from patients, 
clinicians and transplant centre directors using self‐report questionnaires. Methods of patient data 
collection include an interview, self‐report questionnaires, medical chart review and collateral reports by 
nurses and physicians. The methodology in this study is based on the results of several pilot studies 
(Schmid‐Mohler et al. 2010, Ducci et al. 2013). The questionnaire assessing practice patterns, completed 
by centres’ transplant clinicians and directors, was pilot tested in two centres in the USA and in one 
centre in the UK and required only minor editorial adaptations. The patient questionnaires were pilot 
tested with a sample of 58 HTx recipients in Belgium and adapted for 268 liver transplant recipients in 
Italy (Ducci et al. 2013) and 114 kidney transplant recipients in Switzerland (Schmid‐Mohler et al. 2010). 
All instruments used in the BRIGHT study were translated in a culturally sensitive way using the Wild 
protocol (Wild et al. 2005). The instruments are available in English, Dutch, French, German, Italian, 
Spanish and Brazilian Portuguese.  
CIM practice patterns 
The Chronic Illness Management Implementation – Building Research Initiative Group: Chronic 
Illness Management and Adherence in Transplantation (CIMI‐BRIGHT) instrument was developed to 
assess clinicians’ perceptions practice patterns related to CIM (Table S1), the development was based on 
the ICCC framework (Figure 1), a review of the CIM literature and the clinical expertise of the research 
transplantation team (Berben et al. 2014). The instrument passed several validation rounds. Patients’ 
perceptions of CIM practice patterns are assessed by the short version of the Patient Assessment of 
Chronic Illness Care instrument (Gugiu et al. 2009) (Table S1).  
Behavioural factors 
Non‐adherence to immunosuppressive medication is assessed by interview using a validated self‐
report measurement, the Basel Assessment of Adherence with Immunosuppressive Medication Scale
©
 
(BAASIS) (Dobbels et al. 2010, Marsicano Ede et al. 2013) and by the collateral reports of nurses and 
physicians (Table S1) (De Bleser et al. 2011). Non‐adherence to other medications (excluding 
immunosuppressive medications) is assessed using an adapted version of the BAASIS
©
 (Dobbels et al. 
2010, Marsicano Ede et al. 2013) (Table S2). The current level of physical activity is assessed using the 
Brief Physical Activity Assessment Tool (Marshall et al. 2005) (Table S2). Current and former smoking 
status is assessed using an item from the Swiss Health Survey (Swiss Federal Statistical Office 2008) 
(Table S2). Investigator‐developed questions assess current alcohol use, non‐adherence to dietary 
modifications and appointment keeping (Table S2). Sun protection behaviour is assessed using a 
combination of items used in the Swiss Childhood Cancer Registry (Swiss Childhood Cancer Registry) 
and the Cambridge University Hospitals’ Perception of Skin Cancer in Transplant Recipients scale 
(Haque Hussain et al. 2011) (Table S2).  
Correlates of immunosuppressive medication non‐adherence 
Patient level. Based on the IMBP (Figure 3) (Fishbein et al. 2003), correlates of non‐adherence to 
immunosuppressive medications assessed at the patient level are (Table S3) attitudes towards 
immunosuppressive medication intake (investigator‐developed questions), normative beliefs related to 
immunosuppressive medications (investigator‐developed questions based on previous transplant literature 
(Greenstein & Siegal 1998, Gifford et al. 2000, Russell et al. 2003, Butler et al. 2004, Chisholm et al. 
2007, Denhaerynck et al. 2007)), medication taking self‐efficacy (Long‐Term Medication Behavior Self‐
Efficacy Scale (Denhaerynck et al. 2003)), intentions to adhere to immunosuppressive medications 
(investigator‐developed question), barriers in taking immunosuppressive medications as prescribed 
(Immunosuppressive Medication Adherence Barriers scale (The Transplant360 Task Force)), sleep 
quality (item from the Kidney Disease and Quality of Life Short Form (Hays et al. 1997)), daytime 
sleepiness (item adapted from the Dialysis Outcomes and Practice Patterns Study (Elder et al. 2008) and a 
VAS Sleepiness Scale (Zallek et al. 2008)), depression (depression items of the Depression, Anxiety, 
Stress Scale 21‐item version (Gloster et al. 2008)) and health literacy (screening questions of Peterson 
et al. (Peterson et al. 2011)), co‐morbidities (adapted version of the Charlson co‐morbidity index (Fried 
et al. 2001)), readiness to change immunosuppressive medication taking (investigator‐developed 
question). Demographic data on the patient is also collected. The date of the HTx, history of diabetes pre‐
transplant, aetiology of heart failure, the patient's height and weight and the number of treated rejections 
are retrieved by medical chart review.  
  
Healthcare provider level. Factors assessed by patient self‐report (Table S4): patient satisfaction with the 
interpersonal dimension of care (part 1 of the Westaway Patient Satisfaction scale (Westaway et al. 
2003)), trust in the transplant team (Wake Forest University Trust Scale (Hall et al. 2002)) and received 
social support (Social Support Questionnaire (Dobbels et al. 2005)).  
Healthcare organization level. As well as CIM practice patterns, the core competencies of the transplant 
team in chronically ill patient care, including the presence and role of advanced practice nurses are 
collected by clinicians self‐report. Characteristics of the transplant centre are assessed by transplant 
director self‐report. Self‐report demographic information is collected from transplant clinicians (Table 
S5). 
Healthcare system and policy level. Insurance status and perceived treatment‐related financial burden are 
assessed by patient self‐report (Table S6) using items from the Supporting Medication Adherence in 
Renal Transplantation Study questionnaire (Denhaerynck et al. 2007). Cost related non‐adherence is 
assessed by questions used by Wilson et al. (2007) (Table S6). Country specific data such as the type of 
healthcare system, expenditure on health, the density of nurses and physicians per 1000 inhabitants, the 
number of acute beds per 1000 inhabitants and chronic disease mortality rates are retrieved from the 
Organization for Economic Cooperation and Development (OECD) and the Commonwealth Fund 
statistical databases (Table S6). Transplant relevant aggregated country‐level data (e.g. number of HTx 
centres and number of HTx performed) are retrieved from the ISHLT data bases (Table S6).  
Data collection 
Data collection is coordinated and led by the Institute of Nursing Science, University of Basel, 
Switzerland. There are four study phases: 
 
1. Obtaining local IRB approval: Once a centre agrees to participate in the study, the project manager 
works with centre personnel to submit the IRB proposal based on local IRB guidelines. 
2. Training of data collectors: Initially they receive a detailed step by step training manual which is 
followed up by training in their native language via telephone or podcast with backup advice 
available from the BRIGHT study team members by email, phone or Skype as required. 
3. Screening of patients: As soon as IRB approval is received transplant centres are asked to screen all 
patients for inclusion and exclusion criteria and send a coded list of eligible patients to the 
investigators who randomly select a sample, using a computational random number generator. 
4. Data collection: Questionnaire packages are prepared at the Institute of Nursing Science, University 
of Basel, Switzerland. At each centre, data are collected from the selected patients, clinicians and the 
HTx director. 
 
Data collection patient: The purpose of the study is explained to patients during a scheduled outpatient 
visit, they are invited to participate in the study and informed consent is obtained. The BAASIS patient 
interview (Dobbels et al. 2010) is conducted and demographic data are collected by interview. Patients 
receive the patient‐administered BRIGHT questionnaire to complete during the outpatient clinic visit. The 
data collectors collect clinical data from the patient's medical record and ask the nurse and physician to 
complete the collateral report assessing adherence to immunosuppressive medications. Data collection 
HTx director: The director completes the transplant centre director questionnaire. Data collection HTx 
clinicians: The data collector informs the eligible transplant clinicians about the study and, if needed 
(depending on the IRB requirements for the specific centre), obtains informed consent and forwards the 
questionnaire. The clinician places the completed questionnaire in the provided envelope and to seal and 
return it to the data collector. Once data collection is finished, the data collector sends all questionnaires 
back to the data management centre (Institute of Nursing Science, University of Basel, Switzerland).  
  
Data collection for this study started on 28 March 2012 and is ongoing. We anticipate completion by 
autumn 2014. As they completed data collection, each transplant centre receives an intermediate report 
summarizing adherence data for their specific centre. Following completion of the entire study, all centres 
will receive a benchmarking report where they will be able to anonymously compare their performance 
with other centres. The report will be formatted to allow each centre to identify themselves but not other 
centres. 
Data analysis 
Aim 1 & 2: Descriptive analysis will apply appropriate statistics, including measures of location (e.g. 
frequencies, means and percentiles) and dispersion (e.g. standard deviations and IQR) for the total sample 
and by country and centre depending on the level of measurement and data distribution. Data will be 
summarized in tables and figures. 
 
Aim 3: Exploration of the relationship between immunosuppressive medication non‐adherence and its 
possible correlates at the different levels will be performed using generalized linear mixed regression 
analysis. This approach is suited to multi‐level data in that it disentangles overall error into its nested 
components (i.e. individual patients in centres in countries), thus providing stronger evidence for the 
unique association of tested risk factors with non‐adherence. It also allows estimation of the proportion of 
variability at the higher levels that remains unexplained by the variables included and allows testing of 
interactions across levels. 
 
Aim 4: A detailed descriptive analysis will be performed using the appropriate statistics for all 
practice patterns and system level factor variables identified as significantly associated with adherence to 
immunosuppressive medications. Findings will be summarized in tables and figures for each centre. 
 
Software packages used for statistical analysis are IBM Statistics (SPSS, IBM Schweiz AG, 
Vulkanstrasse 106, CH‐8010 Zurich, Switzerland) and SAS (SAS Institute AG, Richtistrasse 11, CH‐
8304 Wallisellen, Switzerland) A P value of <0·05 will be considered as statistically significant. The 
presence of missing data will be mapped and its influence on the results of the modelling explored using 
sensitivity analyses under different possible scenarios.  
Ethical considerations 
Ethical approval is obtained from each participating centres’ IRB/ethics committee prior to data 
collection. The patient information and informed consent forms comply with the guidelines of the 
Declaration of Helsinki (World Medical Organization 1996) and specific national legislation (e.g. 
consideration of Health Insurance Portability and Accountability Act in the US). All participants are 
informed in writing and orally about the aims of the study, why they are selected, what their involvement 
means in terms of data collection, the risks/benefits of taking part and who the contact persons are for the 
study. They are also informed that they have the right to discontinue their participation at any time 
without affecting their treatment by the transplant team or hospital. Safeguards to ensure participant 
confidentiality are explained and written informed consent is obtained from each participant prior to data 
collection.  
  
Validity and reliability 
Several steps are taken to assure the validity and reliability of this study: 
 
First, use of consistent methodology across all centres makes comparisons across centres, countries 
and continents possible. Second, measurements employed in this study have been used in other studies. 
Instruments developed for the purposes of this and other studies were tested for validity and reliability 
using data from the pilot studies or will be tested using data from this current study. Third, a power 
analysis determined the sample size needed to detect a modest association between adherence and the 
level of chronic illness management implemented in the centres. Fourth a proportional randomized 
sampling strategy was used to select patients. Finally, confounding variables will be controlled for by 
entering them as co‐variables in the analysis. 
Discussion 
To the best of our knowledge, this is the first multi‐centre, multi‐continental study assessing practice 
patterns for CIM in HTx programmes. It is the first study assessing patient non‐adherence to different 
aspects of a treatment regimen (medication intake, smoking cessation, diet keeping, limited alcohol 
consumption, increase physical activity, sun protection and appointment keeping) in a large sample of 
HTx recipients across a variety of settings. The consistent methodology in all centres will ensure effective 
comparison of the prevalence of non‐adherence between centres, countries and continents. The sampling 
methodology, recruitment of multiple centres in countries and across continents and the random selection 
of patients in centres, will increase the generalizability of the BRIGHT study findings. The BRIGHT 
study will also examine associations between several selected factors at the patient, healthcare provider, 
healthcare organization and healthcare system and policy levels and immunosuppressive medication non‐
adherence. Inclusion of factors at all levels of the healthcare system will allow us to examine their 
individual contribution and their combined and/or synergistic effect on immunosuppressive medication 
non‐adherence. As the first study of its type, the BRIGHT study results will give a basis for identifying 
factors which can be targeted in future intervention studies. The results of this study also have potential 
implications for clinical practice. The feedback that individual centres will receive about patient specific 
behavioural outcomes (i.e. non‐adherence) can be addressed through practice improvement initiatives. 
Nurses play a key role in outpatient transplant care and in promoting patient self‐management behaviours 
and can use the findings of this study to initiate practice changes designed to improve the care of their 
chronically ill heart transplant recipients. 
Limitations 
A limitation of this large 40 centre survey is not using electronic monitoring to assess one of the 
study's key variables, immunosuppressive medication non‐adherence. This is generally considered the 
most accurate assessment method (Osterberg & Blaschke 2005). However, it is very costly and given the 
size of this study, not feasible. As recommended by Osterberg and Blaschke (Osterberg & Blaschke 2005) 
we are using a combination of other assessment methods (i.e. patient self‐report and collateral report from 
the treating nurse/clinician and the treating physician) to measure adherence to immunosuppressive 
medications. Additionally, the cross‐sectional study design does not allow us to make causal inferences. 
Behaviour might be dynamic and a one point assessment might not entirely reflect health behaviour issues 
in this patient population.  
  
Conclusion 
The BRIGHT study is a cross‐sectional study assessing CIM practice patterns, non‐adherence to 
various aspects of the treatment regimen and multi‐level correlates of immunosuppressive medication 
regimen in 1680 HTx recipients in 40 HTx centres in 11 countries on 4 continents. Data are also collected 
from HTx clinicians and the medical director of the HTx programme. Knowledge gained in this study will 
inform clinicians, researchers and healthcare policy makers at which level interventions to improve 
immunosuppressive medication adherence must be implemented to improve long‐term outcomes for HTx 
patients. 
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